We recently reported that human epididymis protein 4 (HE4) antigen–autoantibody complexes could significantly improve diagnostic performance in combination with CA125 compared with CA125 alone based on analysis of early stage ovarian cancer samples [7]. This evidence concerns the gene MUC16 and ovarian carcinoma.